Helius Medical Technologies, Inc.

Based in the US, Helius Medical Technologies focuses on delivering innovative neurotechnology solutions to address neurologic deficits through non-invasive devices. Founded in 2014, Helius Medical Technologies, Inc. specializes in neurotechnology that offers solutions for neurologic deficits. The company has undergone strategic pivots to enhance its product offerings and is headquartered in the United States.

Its latest funding round was a PIPE totaling USD 0. 720 mn, which is also the total amount raised. The company has completed 3 deals to date. Helius Medical Technologies, Inc.

specializes in innovative neurotechnology aimed at addressing neurologic deficits through non-implantable platform solutions. Their flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers neurostimulation via the tongue to facilitate neuroplasticity and enhance the brain's ability to compensate for functional deficits. This therapeutic device is specifically designed to improve balance and gait in individuals suffering from neurologic conditions, including mild-to-moderate traumatic brain injury and other related disorders. Helius serves a diverse client base that includes healthcare providers and rehabilitation centers, with the PoNS Therapy currently available exclusively in the United States and Canada.

The company has dedicated significant resources to research and development, ensuring that their technology is backed by scientific validation and clinical studies. Helius Medical Technologies generates revenue through the sale of its PoNS® device, marketed to healthcare providers and rehabilitation facilities. The device is typically sold through direct-to-consumer channels and partnerships with medical institutions. Recent reports indicate pricing figures around USD 19,161 for out-of-network claims authorized by major payers such as CignaHealth and Anthem Multiplan.

For the year 2024, the company reported revenue of USD 520,000 and an EBITDA of USD -13,843,000. Helius Medical Technologies aims to expand its product line and enhance its offerings, including potential new devices designed to further support neurologic conditions. The company is also looking to penetrate additional markets beyond the United States and Canada. Recent funding through the PIPE will support these initiatives, although specific release dates or new market locations have not been disclosed.

Additionally, Rockshield Capital has exited its stake in Helius Medical Technologies, with financial terms of the transaction not disclosed.